Home / Compounds / Weight management

Weight management

Weight management covers 4 compounds on WikiPep: Retatrutide, Tirzepatide, Semaglutide and Cagrilintide. Across them, 21 of the 24 uses listed here have been studied in human trials of that compound.

All four act on gut hormones that shape appetite and blood sugar. Semaglutide (GLP-1) and tirzepatide (GLP-1 plus GIP) are FDA-approved. Retatrutide, which adds glucagon, and cagrilintide, a long-acting amylin analog, are investigational. All four have human trials behind their weight-loss figures, and in those trials the dose went up in fixed steps: every four weeks for the three GLP-based drugs.

Appetite and metabolism. Every use below carries an evidence label, so you can see what has been studied in people and what has not.

RetatrutideGLP-1/GIP/glucagon triple agonist 2–12 mg Once weekly, same day 7 uses · 6 human-studied TirzepatideGIP/GLP-1 dual agonist 2.5–15 mg Once weekly, same day 9 uses · 8 human-studied SemaglutideGLP-1 receptor agonist 0.25–2.4 mg Once weekly 4 uses · 4 human-studied CagrilintideLong-acting amylin analog 0.25–2.4 mg Once weekly, same day 4 uses · 3 human-studied

Each one, in plain words

  • Retatrutide: Retatrutide is a once-a-week injection being tested for weight loss. Eli Lilly makes it, and it is not approved yet.
  • Tirzepatide: Tirzepatide is a once-a-week injection for weight loss and type 2 diabetes. It is FDA-approved as Mounjaro and Zepbound.
  • Semaglutide: Semaglutide is a once-a-week injection for weight loss and type 2 diabetes. It is FDA-approved as Ozempic and Wegovy, and as daily tablets.
  • Cagrilintide: Cagrilintide is an experimental once-a-week injection being tested for weight loss. Novo Nordisk makes it, and it is not approved.

Related news

Working out a dose? The calculator turns a vial size and a dose into units on a syringe, and the mixing guide covers reconstitution.